Want to see KR:002720 full AI Analyst Report?
Top Page
KUKJE PHARMA Co., Ltd.
(002720)
Select Model
Select Model
Rating:62Neutral
Price Target:
₩3,657.00
Action:N/A
Date:10/28/26
The score is primarily supported by improving fundamentals (strong TTM revenue rebound and a generally controlled balance sheet), but is held back by weaker cash-flow quality (mixed conversion and steep TTM FCF growth decline) and thin margins. Technically, the stock screens weak due to trading below key moving averages with low momentum indicators, while valuation is moderate and does not materially offset those risks.
Positive Factors
Strong TTM Revenue Rebound
The sharp TTM revenue rebound indicates stronger recent commercial performance and expanding sales activity. Combined with a solid gross margin, this provides a foundation for maintaining product investment and supporting future earnings, although sustained execution will determine how durable the improvement becomes.
Negative Factors
Thin and Compressed Profit Margins
Thin and declining operating and net margins leave limited room to absorb cost increases or weaker demand without affecting earnings. The compression also suggests that recent revenue growth has not translated proportionately into profitability, which may limit durable earnings expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong TTM Revenue Rebound
The sharp TTM revenue rebound indicates stronger recent commercial performance and expanding sales activity. Combined with a solid gross margin, this provides a foundation for maintaining product investment and supporting future earnings, although sustained execution will determine how durable the improvement becomes.
Read all positive factors
KUKJE PHARMA Co., Ltd. (002720) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩69.23B
Dividend Yield0.88%
Average Volume (3M)3.88M
Price to Earnings (P/E)14.2
Beta (1Y)-0.08
Revenue Growth8.02%
EPS Growth-23.36%
CountryKR
Employees272
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)239.89
Shares Outstanding21,159,832
10 Day Avg. Volume2,445,625
30 Day Avg. Volume3,875,000
Financial Highlights & Ratios
PEG Ratio1.65
Price to Book (P/B)0.90
Price to Sales (P/S)0.50
P/FCF Ratio39.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
KUKJE PHARMA Co., Ltd. Business Overview & Revenue Model
Company Description
KUKJE PHARMA Co. Ltd. engages in the manufacture, sale, and distribution of pharmaceutical, cosmetics, and healthcare products. Its products include cephalosporins, penicillins, quinolones, aminoglycosides, macrolides, antibiotics, and antifungal ...
KUKJE PHARMA Co., Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
54
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 181.27B | 175.50B | 156.46B | 135.37B | 126.58B | 119.75B |
| Gross Profit | 96.91B | 92.97B | 82.50B | 67.22B | 63.25B | 54.47B |
| EBITDA | 8.57B | 9.41B | 11.02B | -1.04B | 10.23B | 4.08B |
| Net Income | 5.00B | 5.70B | 5.21B | -8.42B | 3.56B | -1.56B |
Balance Sheet | ||||||
| Total Assets | 185.21B | 190.53B | 165.55B | 163.26B | 136.59B | 139.78B |
| Cash, Cash Equivalents and Short-Term Investments | 15.72B | 10.72B | 8.75B | 10.63B | 5.56B | 7.90B |
| Total Debt | 31.39B | 30.40B | 29.51B | 30.66B | 28.60B | 35.99B |
| Total Liabilities | 85.84B | 92.83B | 76.00B | 78.31B | 62.51B | 71.20B |
| Stockholders Equity | 99.36B | 97.69B | 89.54B | 84.94B | 74.07B | 68.57B |
Cash Flow | ||||||
| Free Cash Flow | 2.32B | 2.22B | 945.21M | 2.53B | 5.23B | 7.64B |
| Operating Cash Flow | 6.69B | 5.84B | 3.94B | 3.58B | 6.50B | 9.60B |
| Investing Cash Flow | -4.89B | -4.16B | -4.76B | -1.18B | -1.35B | -3.38B |
| Financing Cash Flow | 280.96M | 343.87M | -1.20B | 2.61B | -7.47B | -2.43B |
KUKJE PHARMA Co., Ltd. Technical Analysis
Negative
―
Price Trends
3497.50
Negative
3426.30
Negative
3986.56
Negative
Market Momentum
-29.97
Positive
40.97
Neutral
7.21
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:002720, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 3781.00, equal to the 50-day MA of 3497.50, and equal to the 200-day MA of 3986.56, indicating a bearish trend. The MACD of -29.97 indicates Positive momentum. The RSI at 40.97 is Neutral, neither overbought nor oversold. The STOCH value of 7.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:002720.
KUKJE PHARMA Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₩163.98B | 6.30 | ― | 5.19% | 1.00% | -47.42% | |
68 Neutral | ₩703.72B | 9.50 | ― | 1.92% | 6.39% | 29.21% | |
62 Neutral | ₩69.23B | 14.17 | ― | 0.88% | 8.02% | -23.36% | |
57 Neutral | ₩823.50B | 10.36 | ― | 0.80% | 7.15% | 29.88% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | ₩115.34B | -11.04 | ― | 2.39% | 7.15% | 59.41% |
* General Sector Average
KR:002720
KUKJE PHARMA Co., Ltd.
3,345.00
-893.91
-21.09%
KR:002390
Handok, Inc.
8,210.00
-2,996.12
-26.74%
KR:003850
Boryung Corporation
8,310.00
-422.11
-4.83%
KR:023910
Daihan Pharmaceutical Co., Ltd.
24,750.00
-3,435.70
-12.19%
KR:185750
Chong Kun Dang Pharmaceutical Corp.
63,100.00
-19,215.79
-23.34%
KR:234080
JW LIFESCIENCE CORPORATION
10,510.00
-2,381.28
-18.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.